MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA's THIO-101 trial shows 17.8 months median overall survival in NSCLC. New benchmark nearly triples SOC survival data for third-line NSCLC treatment. Accelerated FDA approval possible as early as next year for ateganosine. Treatment demonstrated efficacy and safety with low toxicity in heavily pretreated patients. MAIA's stock increased by 11.7% following positive trial data release.
View signal analysis